Kazia Therapeutics Ltd
Kazia Therapeutics Ltd is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of cancer, primarily in the Asia-Pacific region.
Business. Kazia Therapeutics Ltd (KZIA.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Kazia Therapeutics Ltd (KZIA.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Kazia Therapeutics operates with a negative equity position of -8.3 million AUD and a debt-to-equity ratio of -0.43, indicating a capital structure that is heavily leveraged and reliant on external financing. The company's liquidity position is rated as medium, with a current ratio of 0.35, suggesting limited short-term liquidity to cover immediate obligations. The enterprise value to revenue ratio of 1333.1 is significantly higher than typical industry benchmarks, reflecting a high valuation relative to its current revenue base.
Profitability metrics for Kazia Therapeutics are weak, with a net loss of 20.7 million AUD and an operating loss of 24.03 million AUD in the latest reporting period. The return on equity of 2.49% is modest and indicates that the company is generating minimal returns for its shareholders. The return on assets of -3.42% further underscores the company's inability to generate positive returns from its asset base.
Kazia Therapeutics derives its revenue primarily from the Asia-Pacific region, where it has a strong commercial presence. The company's revenue concentration in this region exposes it to regional economic and regulatory risks. The company does not disclose detailed segment information, but its operations are focused on oncology drug development and commercialization.
The company's growth trajectory is uncertain, with a negative operating cash flow of 13.28 million AUD and a free cash flow of -19.77 million AUD, indicating that it is not generating sufficient cash from operations to sustain its activities. The outlook for the current fiscal year is negative, with no clear signs of improvement in the near term.
Kazia Therapeutics faces several risk factors, including its negative net cash position and the need for ongoing external financing. The company's dilution risk is currently rated as low, but the potential for future dilution remains a concern due to the company's reliance on equity financing. The company's financial position is further complicated by its negative equity and high debt levels.
Recent events and filings indicate that Kazia Therapeutics is actively engaged in clinical trials and regulatory submissions for its drug candidates. The company has also been in discussions with potential partners to advance its pipeline. Despite these efforts, the company's financial performance remains a significant concern for investors.
- Kazia Therapeutics has a negative equity position and a high debt-to-equity ratio, indicating a capital structure that is heavily reliant on external financing.
- The company's profitability metrics are weak, with a net loss and an operating loss in the latest reporting period.
- Kazia Therapeutics is focused on the Asia-Pacific region, which exposes it to regional economic and regulatory risks.
- The company's liquidity position is rated as medium, with a current ratio of 0.35, suggesting limited short-term liquidity to cover immediate obligations.
- Kazia Therapeutics faces significant financial risks, including its negative net cash position and the need for ongoing external financing.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,12 |
| Revenue | —no estimate | —no estimate | 280,500 UNKNOWN ERROR IN UNIVERSE PROCESSING |
| Operating income | —no estimate | —no estimate | -22,8M UNKNOWN ERROR IN UNIVERSE PROCESSING |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Chief Scientific Officer · Employee Stock Option (right to buy) → ADSsAcquired 250 000 @ $18,48grant · 2026-06-19
- Chief Financial Officer · Employee Stock Option (right to buy) → ADSsAcquired 200 000 @ $13,86grant · 2026-06-19
- Director · Employee Stock Option (right to buy) → ADSsAcquired 100 000 @ $9,10grant · 2026-01-08
- Director · Employee Stock Option (right to buy) → ADSsAcquired 100 000 @ $9,10grant · 2026-01-08
- Chief Executive Officer · Employee Stock Option (right to buy) → ADSsAcquired 500 000 @ $6,78grant · 2026-01-08
- Chief Executive Officer · Restricted Share Units → ADSsDisposed 150 000grant · 2026-01-08
- VP, Finance and Controller · Employee Stock Option (right to buy) → ADSsAcquired 150 000 @ $6,78grant · 2026-01-08
- Director, CMC · Employee Stock Option (right to buy) → ADSsAcquired 100 000 @ $9,10grant · 2026-01-08
- Director · Employee Stock Option (right to buy) → ADSsAcquired 75 000 @ $6,78grant · 2026-01-08
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Kazia Therapeutics Ltd Market data — financials · 2026-05-28
- Kazia Therapeutics Ltd Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M